Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:44 PM ET 10-Q
Financial Results Bain Capital Specialty Finance, Inc. BCSF

Bain Capital Specialty Finance Q3 2026 Results: Net Income $16.7M, Down 10.7% YoY

For the nine months ended September 30, 2026, Bain Capital Specialty Finance reported total investment income of $188.4 million and net investment income of $83.7 million. The company's net asset value per share decreased to $16.49 from $17.23 at the end of 2025, primarily driven by net realized and unrealized losses on investments.

Key figure
Net income $16.7M · -10.7% YoY
4:43 PM ET Form 4
Insider Selling OneSpan Inc. OSPN

OneSpan General Counsel Lara Mataac Sells $114K of Stock

Lara Mataac, General Counsel, sold 4,990 shares of OneSpan Inc. at $22.77 a share, worth $114K in total on Nov 9, 2026. Shares held after the trade: 71,060 (-6.6%).

Value
$114K
Shares
4,990
Price
$22.77
Role
General Counsel
Holding change
-6.6%
Trade date
Nov 9, 2026
4:43 PM ET 8-K
Executive Compensation NIKE, Inc. NKE

NIKE Executive Compensation

NIKE, Inc. appointed Dan McKenzie as Vice President, Chief Accounting Officer, and principal accounting officer, effective November 9, 2026. McKenzie's compensation package includes a $500,000 base salary, a 50% target annual bonus, and one-time RSU awards totaling approximately $1.125 million in target value. He succeeds David Denton, who had been serving as the Interim Corporate Controller.

4:42 PM ET 8-K
M&A Deal Atii Holdings Inc. NANO

Forge Nano Holdings Signs $55M M&A Deal with HzO, Inc.

Forge Nano Holdings, Inc. completed the acquisition of HzO, Inc. on November 4, 2026, through a merger of a wholly owned subsidiary into HzO. The transaction was valued at an aggregate purchase price of $55.0 million, paid through the issuance of 7,306,440 shares of Forge Nano common stock to HzO security holders.

Value
$55M
Counterparty
HzO, Inc.
4:41 PM ET 10-Q
Financial Results Baldwin Insurance Group, Inc. BWIN

Baldwin Insurance Group Q3 2026 Results: Net Loss of $58.1M, Loss Widens

The Baldwin Insurance Group, Inc. reported total assets of $5.94 billion as of September 30, 2026, a significant increase from $3.86 billion at year-end 2025, driven largely by growth in goodwill and intangible assets. The company also announced a definitive Merger Agreement dated September 14, 2026, to undergo a 'Go-Private Transaction' where it will become a wholly owned subsidiary of Square Acquisition Parent, Inc.

Key figure
Net loss $58.1M
4:41 PM ET 10-Q
Financial Results American Vanguard Corp AVD ▶ Call

American Vanguard Q3 2026 Results: Net Loss of $17.7M, Loss Widens

American Vanguard reported a net loss of $17.7 million for the third quarter of 2026, compared to a net loss of $12.4 million in the prior year period, as net sales declined by 9% to $108.4 million. The company's financial performance was impacted by higher interest expenses and transformation costs, resulting in a year-to-date net loss of $31.7 million.

Key figure
Net loss $17.7M
4:40 PM ET 8-K/A
M&A Deal Zymeworks Inc. ZYME

Zymeworks M&A Deal with Theravance Biopharma, Inc.

Zymeworks Inc. filed an amendment to its previous 8-K to provide historical and pro forma financial statements following its completed acquisition of Theravance Biopharma, Inc. The merger involved a cash payment of $17.00 per share plus a contingent value right (CVR) tied to the future monetization and commercial success of ampreloxetine. The cash portion of the deal was financed through $350 million in non-recourse notes from OMERS Life Sciences and existing cash reserves.

Counterparty
Theravance Biopharma, Inc.
4:40 PM ET 10-Q
Financial Results DocGo Inc. DCGO

DocGo Q3 2026 Results: Net Loss of $16.6M, Loss Narrows

DocGo Inc. reported a net loss of $18.3 million for the quarter ended September 30, 2026, on revenues of $73.4 million, compared to a net loss of $29.7 million on revenues of $70.8 million in the prior year period. The company's cash position decreased significantly from $51.0 million at year-end 2025 to $19.1 million as of September 30, 2026.

Key figure
Net loss $16.6M
4:40 PM ET 10-Q
Financial Results NRG Energy, Inc. NRG

NRG Energy Q3 2026 Results: Net Income $561M, Up 269.1% YoY

NRG Energy reported a significant increase in revenue to $9.47 billion for the third quarter of 2026, up from $7.64 billion in the prior year, driven by strategic acquisitions including the Texas Generation Portfolio. Net income available for common stockholders rose to $544 million for the quarter, while the company's total assets expanded to $40.3 billion following substantial investments in property, plant, and equipment.

Key figure
Net income $561M · +269.1% YoY
4:39 PM ET Form 4
Insider Selling Calix, Inc CALX

Calix Insider Carl Russo Sells $2.33M of Stock

Carl Russo sold 75,000 shares of Calix, Inc at $31.03 to $31.88 a share (average $31.07) in 2 transactions, worth $2.33M in total on Nov 6, 2026. Shares held after the trade: 1,494,188 (-0.2%).

Value
$2.33M
Shares
75,000
Average price
$31.07
Holding change
-0.2%
Trade date
Nov 6, 2026
4:39 PM ET 10-Q
Financial Results Lafayette Square USA, Inc.

Lafayette Square USA Q3 2026 Results: Net Loss of $13.7M

Lafayette Square USA, Inc. reported total assets of $1.17 billion as of September 30, 2026, with a net asset value per share of $13.81. The company experienced a decrease in net assets from $411.3 million at year-end 2025 to $475.1 million, though distributable earnings shifted to a loss of $33.2 million during the period.

Key figure
Net loss $13.7M
4:38 PM ET 8-K
Leadership Change Pangaea Logistics Solutions Ltd. PANL

Pangaea Logistics Solutions Leadership Change

Richard T. du Moulin, Chair of the Board of Directors, has notified the company of his decision to retire effective December 31, 2026. Mr. du Moulin has served as a director since the company's IPO in 2014 and has been affiliated with the firm for over 25 years.

4:38 PM ET 10-Q
Financial Results HF Foods Group Inc. HFFG

HF Foods Group Q3 2026 Results: Net Loss of $4.22M, Loss Widens

HF Foods Group Inc. reported a net loss of $4.2 million for the quarter ended September 30, 2026, compared to a $0.9 million loss in the prior year period. While total net revenue increased to $319.6 million, the company faced higher distribution, selling, and administrative expenses, as well as increased interest costs.

Key figure
Net loss $4.22M
4:37 PM ET 10-Q
Financial Results FiscalNote Holdings, Inc. NOTE

FiscalNote Holdings Q3 2026 Results: Net Loss of $5.88M, Loss Narrows

FiscalNote Holdings reported a significant decline in total assets from $255.1 million to $162.3 million between December 2025 and September 2026, primarily driven by a $59.1 million goodwill impairment. The company faces substantial liquidity risks, reclassifying $98.7 million of long-term debt to current maturities due to existing defaults and potential creditor enforcement actions.

Key figure
Net loss $5.88M
4:37 PM ET 10-Q
Financial Results Digital Turbine, Inc. APPS

Digital Turbine Q2 2026 Results: Turns Profitable, Net Income $10.3M

Digital Turbine reported net revenue of $178.7 million for the quarter ended September 30, 2026, a significant increase from $140.4 million in the prior year period. While the company achieved a quarterly net income of $10.3 million, it recorded a net loss of $3.0 million for the six-month period, reflecting ongoing volatility in derivative valuations and interest expenses.

Key figure
Net income $10.3M
4:36 PM ET 8-K
Financial Results Bakkt, Inc. BKKT

Bakkt Financial Results

Bakkt reported Q3 2026 financial results, highlighted by GAAP net income of $14.3 million and a 40% year-over-year reduction in core operating expenses. The company reiterated its full-year 2026 Total Transacting Volume (TTV) target of $3 billion and established a new 1H 2027 TTV target of $6 billion, driven by accelerating client activations in institutional and cross-border segments.

Term
Q3 2026

“The foundation is built, and the commercial ramp is underway. The measure that matters from here is volume: we are reiterating our target of approximately $3 billion of Total Transacting Volume for 2026, setting a target of approximately $6 billion for the first half of 2027, and we will report what we deliver every month.”

Akshay Naheta, CEO of Bakkt

“Our third-quarter results reflect a lower operating cost base year over year and a balance sheet with no long-term debt. Operating expenses excluding crypto costs and execution, clearing and brokerage fees were $16.1 million, down 40% from the prior-year quarter, and our Adjusted EBITDA loss narrowed by $3.0 million to $11.8 million on a consistent basis.”

Matt White, CFO of Bakkt
4:36 PM ET 10-K
Financial Results Apex Tech Acquisition Inc. TRAD

Apex Tech Acquisition FY 2026 Results: Turns Profitable, Net Income $734K

APEX Tech Acquisition Inc. is a blank check company that has entered into a merger agreement with Korai Flix, Inc., though it faces substantial doubt about its ability to continue as a going concern due to a $338,372 working capital deficit and limited cash. The company must complete the business combination by May 25, 2027, or face liquidation, with the closing subject to shareholder approval and minimum net asset conditions.

Key figure
Net income $734K
4:36 PM ET 8-K
Financial Results Mesa Laboratories Inc MLAB

Mesa Laboratories Financial Results

Mesa Laboratories reported second quarter fiscal 2027 results with revenues increasing 2.6% to $62.3 million and net income rising 75.3% to $4.3 million. The company issued full-year fiscal 2027 guidance for the first time, forecasting revenues between $250 million and $255 million. Performance was driven by record revenues in the Sterilization and Disinfection Control division, partially offset by export-control delays in the Biopharmaceutical Development segment.

Term
Q2 2027

“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”

Dr. Siddhartha Kadia, President and CEO

“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”

John Sakys, Chief Financial Officer
4:36 PM ET 8-K
Financial Results Ranger Energy Services, Inc. RNGR

Ranger Energy Services Financial Results

Ranger Energy Services reported Q3 2026 revenue of $162.8 million and net income of $2.5 million, while generating $20.0 million in free cash flow. During the period, the company completed the acquisition of STEP Energy Services' US coil tubing assets and declared a quarterly dividend of $0.06 per share.

Term
Q3 2026

“The past few months have marked meaningful strategic progress for Ranger. We completed the STEP coil tubing acquisition and are now positioned as the second largest coil tubing provider in the lower 48 market, expanded our contracted ECHO fleet further establishing a competitive advantage in the next generation of well-servicing equipment and navigated a challenging competitive dynamic.”

Stuart Bodden, Ranger’s Chief Executive Officer
4:36 PM ET 10-Q
Financial Results Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens

Perspective Therapeutics reported a net loss of $85.4 million for the nine months ended September 30, 2026, compared to $65.6 million in the prior year period, primarily driven by increased research and development expenses. The company significantly strengthened its balance sheet through a 2026 registered offering, ending the period with $201.7 million in cash, cash equivalents, and short-term investments.

Key figure
Net loss $32.4M
4:36 PM ET 10-Q
Financial Results AbCellera Biologics Inc. ABCL

AbCellera Biologics Q3 2026 Results: Net Loss of $40.8M, Loss Narrows

AbCellera Biologics Inc. reported total revenue of $23.0 million for the nine months ended September 30, 2026, a decrease from $30.3 million in the prior year period. The company recorded a net loss of $151.3 million for the first nine months of 2026, driven by significant research and development expenses of $136.2 million as it advances its internal drug candidate pipeline, including ABCL635.

Key figure
Net loss $40.8M
4:35 PM ET 10-Q
Financial Results Bakkt, Inc. BKKT

Bakkt Q3 2026 Results: Turns Profitable, Net Income $14.3M

Bakkt, Inc. filed its 10-Q for the period ending September 30, 2026, highlighting the integration of Distributed Technologies Research Global Ltd. (DTR) and expansion into international markets. The company reported 45,126,712 shares of Class A Common Stock outstanding as of October 30, 2026, and noted significant risks related to digital asset price volatility and regulatory uncertainty.

Key figure
Net income $14.3M
4:34 PM ET Form 4
Insider Selling Slide Insurance Holdings, Inc. SLDE

Slide Insurance Holdings Director Beth Witte Bruce Sells $682K of Stock

Beth Witte Bruce, Director, sold 25,000 shares of Slide Insurance Holdings, Inc. at $27.26 a share, worth $682K in total on Nov 5, 2026. Shares held after the trade: 154,645 (-13.9%).

Value
$682K
Shares
25,000
Price
$27.26
Role
Director
Holding change
-13.9%
Trade date
Nov 5, 2026
4:34 PM ET 10-Q
Financial Results Tg Therapeutics, Inc. TGTX

Tg Therapeutics Q3 2026 Results: Net Income $55.5M, Down 85.8% YoY

TG Therapeutics is focused on the commercialization of BRIUMVI for relapsing forms of multiple sclerosis and the development of its subcutaneous formulation and azer-cel. The company has a history of losses but is utilizing its commercial infrastructure to expand market acceptance while managing significant debt obligations and clinical trial expenses.

Key figure
Net income $55.5M · -85.8% YoY
4:34 PM ET 8-K
Dividend Genuine Parts Co GPC

Genuine Parts Dividend

Genuine Parts Company's Board of Directors declared a regular quarterly cash dividend of $1.0625 per share on its common stock. The dividend is payable on January 5, 2027, to shareholders of record as of December 4, 2026.

4:34 PM ET 10-Q
Financial Results Jbs N.V. JBS

Jbs Q3 2026 Results: Net Income $189M, Down 70.7% YoY

For the nine-month period ended September 30, 2026, JBS N.V. reported net revenue of $68.2 billion, a 8.1% increase over the prior year, though net income fell significantly to $334.3 million from $1.79 billion. The decline was driven by higher cost of sales and increased net finance expenses, resulting in basic earnings per share of $0.26 compared to $1.45 in 2025.

Key figure
Net income $189M · -70.7% YoY
4:34 PM ET 8-K
Financial Results Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Financial Results

Perspective Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $202 million which is expected to fund operations into 2028. The company reported a net loss of $24.7 million for the quarter and provided clinical updates on its lead radiopharmaceutical programs, including bamzireotide navoxetan and lapemelanotide zapixetar.

Term
Q3 2026

“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform. With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”

Thijs Spoor, Perspective’s Chief Executive Officer
4:34 PM ET 8-K
Leadership Change Unitedhealth Group Inc UNH

Unitedhealth Group Leadership Change

UnitedHealth Group Incorporated appointed Madeline Bell, the former president and CEO of Children’s Hospital of Philadelphia, to its Board of Directors as an independent director. Ms. Bell brings over four decades of healthcare experience, including leadership of a premier pediatric health system, to the board. She will receive compensation in accordance with the company's standard program for non-employee directors.

Counterparty
Madeline Bell
4:34 PM ET Form 4
Insider Buying First Guaranty Bancshares, Inc. FGBI

First Guaranty Bancshares Insider Edgar R. Smith III Buys $59K of Stock

Edgar R. Smith III bought 5,000 shares of First Guaranty Bancshares, Inc. at $11.80 a share, worth $59K in total on Nov 6, 2026. Shares held after the trade: 2,872,467 (+0.2%).

Value
$59K
Shares
5,000
Price
$11.80
Holding change
+0.2%
Trade date
Nov 6, 2026
4:34 PM ET 10-Q
Financial Results Puma Biotechnology, Inc. PBYI

Puma Biotechnology Q3 2026 Results: Net Income $5.96M, Down 32.7% YoY

Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026, driven primarily by NERLYNX product sales. While the company remained profitable with a net income of $6.0 million, this was a decrease from $8.8 million in the prior year's third quarter due to higher research and development expenses.

Key figure
Net income $5.96M · -32.7% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.